PHARMACOLOGY UPDATE

Aducanumab-avwa Injection (Aduhelm)

July 15, 2021

The FDA has approved a new, but controversial, treatment for Alzheimer’s disease.

Issue Date: July 15, 2021

Table of Contents

The Effect of Antiviral Drugs on COVID-19 Outcomes and Mortality
Air Filters and Asthma
Using Procalcitonin to Limit Antibiotic Treatment for Sepsis Reduces Infection-Related Adverse Events
Aducanumab-avwa Injection (Aduhelm)
Determining the ‘Culprit’ Artery

Financial Disclosure: Dr. Brunton, physician editor, reports he is on the speakers bureau for AstraZeneca, Bayer, Lilly, and Novo Nordisk; and is a retained consultant for Abbott, Acadia, AstraZeneca, Bayer, Novo Nordisk, Sanofi, and Xeris. The relevant financial relationships listed have been mitigated. None of the remaining planners or authors for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Subscription Publication Books & Study Guides Group & Site Licenses State CME/CE Requirements